ReviewDrug design, development and therapy2015

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.

Timothy S Leung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.